Cockroaches and rodent droppings among reasons for Closure Orders on food businesses in August
Search
11 Sept 2025
Search
11 Sept 2025
Please allow ads as they help fund our trusted local news content.
Kindly add us to your ad blocker whitelist.
If you want further access to Ireland's best local journalism, consider contributing and/or subscribing to our free daily Newsletter .
Support our mission and join our community now.
To continue reading this article, you can subscribe for as little as €0.50 per week which will also give you access to all of our premium content and archived articles!
Alternatively, you can pay €0.50 per article, capped at €1 per day.
Thank you for supporting Ireland's best local journalism!
Pharmaceutical bosses have said research and development (R&D) in the UK sector risks “losing out to other countries” amid concerns over the investment environment.
The warning came as research indicated the UK has lost ground against other countries regarding investment in pharmaceuticals and life sciences.
A study from PwC and the Association of the British Pharmaceutical Industry (ABPI) pointed towards weaker investment in recent years, with a particular fall in foreign funding.
The research indicated UK pharmaceutical investment has underperformed against global trends since 2018.
Latest figures showed that investment in R&D in the sector fell by nearly £100 million in 2023.
It also showed direct foreign investment into UK life science fell by 58% to £795 million from 2017 to 2023.
The data showed the UK ranked second for foreign investment in 2017 and 2021 compared with other countries, but fell to seventh by 2023.
ABPI chief executive Richard Torbett said the Government and industry need to work together to “remove existing barriers” in order to help the sector.
He said: “The UK has a world-class science base and the potential to lead globally in developing the next generation of medicines and vaccines.
“But without a more competitive environment for investment, we risk losing out to other countries making bold moves to attract internationally mobile investment.
“I believe UK has the potential to unlock billions in additional investment in early-stage R&D, ensure patients and the NHS can benefit from access to cutting-edge clinical trials and attract major capital investment in R&D and medicines manufacturing facilities – all of which directly support the government’s health and growth missions.”
AstraZeneca UK president Tom Keith-Roach said: “New and innovative medicines are essential to improving patient outcomes and have huge potential to boost British economic growth and support delivery of the NHS 10 year plan.
“The competitiveness framework underscores the importance of investing in the next generation of medicines and pulling them through to the patients who can benefit.”
Subscribe or register today to discover more from DonegalLive.ie
Buy the e-paper of the Donegal Democrat, Donegal People's Press, Donegal Post and Inish Times here for instant access to Donegal's premier news titles.
Keep up with the latest news from Donegal with our daily newsletter featuring the most important stories of the day delivered to your inbox every evening at 5pm.
This publication supports the work of the Press Council of Ireland and Office of the Press Ombudsman, and our staff operate within the Code of Practice of the Press Council. You can obtain a copy of the Code, or contact the Council, at www.presscouncil.ie, Lo-call 1800 208 080 or email: info@presscouncil.ie.
